Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Control of nausea with palonosetron versus granisetron, both combined with dexamethasone, in patients receiving cisplatin- or anthracycline plus cyclophosphamide-based regimens.
Kubota K, Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T. Kubota K, et al. Among authors: saito m. Support Care Cancer. 2016 Sep;24(9):4025-33. doi: 10.1007/s00520-016-3203-5. Epub 2016 Apr 29. Support Care Cancer. 2016. PMID: 27129842 Free PMC article. Clinical Trial.
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S. Saito M, et al. Lancet Oncol. 2009 Feb;10(2):115-24. doi: 10.1016/S1470-2045(08)70313-9. Epub 2009 Jan 8. Lancet Oncol. 2009. PMID: 19135415 Clinical Trial.
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.
Inoue K, Nakagami K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Miura S, Eguchi K, Shinkai T, Ando M, Watanabe T, Masuda N, Ohashi Y, Sano M, Noguchi S. Inoue K, et al. Among authors: saito m. Breast Cancer Res Treat. 2010 Jan;119(1):127-36. doi: 10.1007/s10549-009-0498-7. Epub 2009 Aug 19. Breast Cancer Res Treat. 2010. PMID: 19690954 Clinical Trial.
[The survey for anti-emetic guideline by using questioner].
Saeki T, Tamura K, Aiba K, Aogi K, Iino K, Imamura C, Eguchi K, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Matsuura K, Wada M, Akechi T, Kakudo Y, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Saito M, Ashikaga Y, Tanigawara Y, Hirata K, Ishioka C, Nishiyama M. Saeki T, et al. Among authors: saito m. Gan To Kagaku Ryoho. 2015 Mar;42(3):305-11. Gan To Kagaku Ryoho. 2015. PMID: 25812498 Japanese.
Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial.
Yamamoto D, Sato N, Rai Y, Yamamoto Y, Saito M, Iwata H, Masuda N, Oura S, Watanabe J, Hattori S, Matsuura Y, Kuroi K. Yamamoto D, et al. Among authors: saito m. Breast Cancer Res Treat. 2017 Feb;161(3):473-482. doi: 10.1007/s10549-016-4075-6. Epub 2016 Dec 22. Breast Cancer Res Treat. 2017. PMID: 28005247 Clinical Trial.
Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Tamura K, Inoue K, Masuda N, Takao S, Kashiwaba M, Tokuda Y, Iwata H, Yamamoto N, Aogi K, Saeki T, Nakayama T, Sato N, Toyama T, Ishida T, Arioka H, Saito M, Ohno S, Yamauchi H, Yamada K, Watanabe J, Ishiguro H, Fujiwara Y. Tamura K, et al. Among authors: saito m. Cancer Sci. 2017 May;108(5):987-994. doi: 10.1111/cas.13221. Epub 2017 May 5. Cancer Sci. 2017. PMID: 28256066 Free PMC article. Clinical Trial.
Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracycline/cyclophosphamide regimen (JTOP-B).
Ozeki R, Iihara H, Shimokawa M, Hashimoto H, Abe M, Mukohara T, Bando H, Hayashi T, Kawazoe H, Komoda M, Yanai Takahashi T, Saito M. Ozeki R, et al. Among authors: saito m. BMJ Open. 2022 Mar 2;12(3):e058755. doi: 10.1136/bmjopen-2021-058755. BMJ Open. 2022. PMID: 35236735 Free PMC article.
8,405 results